View / Download
pdf version of this correspondence
Quality indicators for opioid prescribing
Re: “Helping patients cope with chronic non-malignant pain: it’s not
about opioids”, BPJ 63 (Sep, 2014).
Thank you for this very useful and comprehensive article. There is now a new tool available in New Zealand, not mentioned
in the article, which can be used by individual practitioners or by their services to improve the quality of prescribing
for chronic non-malignant pain.
With funding from the Health Quality and Safety Commission, seven suites of indicators were developed in 2012 to facilitate
safer prescribing of opioids in this context. The indicators identify appropriate numerators and denominators and list
the caveats in indicator implementation and interpretation of the results. The indicators are arranged in suites of related
indices and cover important topic areas, aligned to the 10 Universal Precautions outlined in Pages 36 and 37 of the BPJ
article. The indicators are appropriate for use in an audit cycle with the intention of continuous quality improvement.
Any practitioners, specialists or generalists, are able to access these indicators on the HQSC website and use them for
quality improvement and to ensure that their patients with chronic pain are offered appropriate and evidence-based advice
and support during their convalescence.
The resources are available from:
Drs Helen Moriarty and Roshan Perera,
Early treatment in Parkinson’s disease
Firstly, I hope your beautifully illustrated Best Practice never totally goes out of print.
To show that the copies are treasured, in [The Year in Review - What did we learn in 2014, BPJ 66, Feb, 2015] it is
summarised that Parkinson’s disease should be detected and treated early.
Actually the original article in BPJ 58 (Feb, 2014) states that: “There is little evidence that treatment with either
levodopa or long-acting dopamine agonists in the early phases of Parkinson’s disease results in improved long-term outcomes”
You see - your publications are not in vain!
Dr John Sarfati, General Practitioner
Thank you for your comments. You are correct in pointing this out. In patients with Parkinson’s disease, symptoms should generally begin to be
managed once they become troubling to the patient. Early treatment does not necessarily result in better outcomes, and medicines used to manage
Parkinson’s disease are associated with adverse effects. Treatments are optimised as new symptoms develop. A combination of levodopa with
carbidopa or benserazide is generally first-line treatment for functional disabilities, and then dopamine agonists such as ropinirole or
pramipexole may be added to reduce motor symptoms and minimise the adverse effects of levodopa treatment (younger patients may be started
on dopamine agonists). Additional pharmacological treatments for non-motor symptoms and other strategies, such as dietary adjustments,
physiotherapy and counselling, are all important aspects of management as the patient’s condition worsens.
A special thank you to all of the readers who expressed their support for retaining a printed version of Best Practice Journal,
and also to those who reassured us that they would read our articles online. We really appreciate the feedback, and we
will continue to work hard to provide you with the best evidence-based guidance for primary care.
Send your letters to...
Correspondence, PO Box 6032, Dunedin, 9059
or email firstname.lastname@example.org